ZD-6474. AstraZeneca.

Article Details

Citation
Copy to clipboard

Bates D

ZD-6474. AstraZeneca.

Curr Opin Investig Drugs. 2003 Dec;4(12):1468-72.

PubMed ID
14763134 [ View in PubMed
]
Abstract

ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors. Phase II trials in non-small-cell lung cancer, small-cell lung cancer and myeloma were ongoing in January 2003.

DrugBank Data that Cites this Article

Drugs